Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine after PCI with incomplete revascularization in chronic angina
NL-OMON39458Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in angina pectoris and coronary arteriosclerosis comparing Ranolazine + standard medical therapy with Placebo + standard medical therapy (2 arms). Primary endpoint: Time to first ischemia-driven revascularization or ischemia-driven hospitalization without revascularization. Started Jun 2012; status: active, not recruiting.
02
Drugs
ranolazine
03
Conditions
angina pectoriscoronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON39458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39458.